Applied Optoelectronics (AAOI) delivered earnings and revenue surprises of +10.00% and -1.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...
Innodata (INOD) delivered earnings and revenue surprises of +71.43% and +4.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Shares of Fortinet (NASDAQ: FTNT), a cybersecurity company, tumbled today after the company reported its third-quarter ...
Australia's biggest investment bank Macquarie Group recorded a 3% rise in first-half profit but missed expectations after the bank's earnings were hit by a sharp drop in commodity and markets trading ...
AMC Entertainment Holdings (NYSE: AMC) reported third-quarter results that beat revenue expectations but highlighted the ...
Management noted five major hyperscale customers are now engaged. In the AI and cloud infrastructure race, that’s the ...
Rockwell Automation (NYSE: ROK) beats Q4 FY25 adjusted EPS estimates with $3.34, reports $2.316B revenue, ARR up 8%, and ...
Zacks Investment Research on MSN
DraftKings (DKNG) Reports Q3 Loss, Lags Revenue Estimates
DraftKings (DKNG) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.6 per share a year ago. These figures are ...
Zacks Investment Research on MSN
Inuvo, Inc (INUV) Reports Q3 Loss, Misses Revenue Estimates
Inuvo, Inc (INUV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago. These figures are ...
24/7 Wall St. on MSN
5 High-Yield Blue-Chip Dividend Giants Set to Soar If Rates Fall to 3%
With the Fed likely to be lowering rates until next summer, now is the time to load up on five of our favorite blue-chip ...
Genpact maintained its adjusted income from operations margin outlook at approximately 17.4% for the full year. During the quarter, the company repurchased approximately 2.0 million common shares for ...
Sun Pharma's strong Q2-FY25 results exceed estimates, prompting a target price revision to ₹2,000 by InCred Equities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results